DUBLIN--(BUSINESS WIRE)--The "PD-1 x VEGF and PD-L1 x VEGF Bispecific Antibodies: A Business, Pipeline And Competitor Analysis From An Industry Perspective" report has been added to ...

KOD’s Tarcocimab Tedromer is an anti-vascular endothelial growth factor [anti-VEGF] antibody biopolymer conjugate that’s currently in Phase 3. This candidate is being tested in KOD’s GLOW ...

Enhertu already has seven FDA approvals across breast cancer, gastric cancer, non-small cell lung cancer (NSCLC), and ...

Ivonescimab and the PD-1/VEGF bispecific antibodies have been a hot topic ever since Summit's partner Akesobio generated impressive phase 3 results in a head-to-head trial against Merck’s (MRK ...

The antibody has shown promising results in preclinical studies, demonstrating 'superior' anti-tumour activity.

The report delivers a comprehensive analysis of global biologics sales. Covering cancer antibodies, non-TNF inflammatory mAbs, biosimilars, gene therapy, RNA-based drugs, and more, the report provides ...

CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, today announced that the first patient ...

Tharimmune (THAR) announced the expansion of its product pipeline with HS1940, a dual-target multispecific biologic engineered to bind to both ...

Top-line Phase 2/3 data readout for COMPANION-002, evaluating tovecimig (CTX-009 - a DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer (BTC), is on track for the end of the ...